These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35347987)

  • 1. Identification of Potent DNA Gyrase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Apr; 62(7):1680-1690. PubMed ID: 35347987
    [No Abstract]   [Full Text] [Related]  

  • 2. Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against
    Pakamwong B; Thongdee P; Kamsri B; Phusi N; Taveepanich S; Chayajarus K; Kamsri P; Punkvang A; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2024 Aug; 64(15):5991-6002. PubMed ID: 38993154
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioisosteric Design Identifies Inhibitors of
    Kamsri B; Pakamwong B; Thongdee P; Phusi N; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Sangswan J; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Leanpolchareanchai J; Goudar KE; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2023 May; 63(9):2707-2718. PubMed ID: 37074047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.
    Gl B; Rajput R; Gupta M; Dahiya P; Thakur JK; Bhatnagar R; Grover A
    Biochem J; 2020 Nov; 477(21):4167-4190. PubMed ID: 33030198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis.
    Kashyap A; Singh PK; Silakari O
    Tuberculosis (Edinb); 2018 Sep; 112():83-88. PubMed ID: 30205973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual Screening Identifies Novel and Potent Inhibitors of
    Thongdee P; Hanwarinroj C; Pakamwong B; Kamsri P; Punkvang A; Leanpolchareanchai J; Ketrat S; Saparpakorn P; Hannongbua S; Ariyachaokun K; Suttisintong K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Mukamolova GV; Blood RA; Takebayashi Y; Spencer J; Mulholland AJ; Pungpo P
    J Chem Inf Model; 2022 Dec; 62(24):6508-6518. PubMed ID: 35994014
    [No Abstract]   [Full Text] [Related]  

  • 7. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
    Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis.
    Kashyap A; Singh PK; Satpati S; Verma H; Silakari O
    J Cell Biochem; 2019 Mar; 120(3):3149-3159. PubMed ID: 30191589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and antitubercular activity of 4-alkoxy-triazoloquinolones able to inhibit the M. tuberculosis DNA gyrase.
    Carta A; Bua A; Corona P; Piras S; Briguglio I; Molicotti P; Zanetti S; Laurini E; Aulic S; Fermeglia M; Pricl S
    Eur J Med Chem; 2019 Jan; 161():399-415. PubMed ID: 30384044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Matrat S; Brossier F; Bastian S; Reitter D; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4524-9. PubMed ID: 21768507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors.
    Jeankumar VU; Kotagiri S; Janupally R; Suryadevara P; Sridevi JP; Medishetti R; Kulkarni P; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Feb; 23(3):588-601. PubMed ID: 25541204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria.
    Sterle M; Habjan E; Piga M; Peršolja P; Durcik M; Dernovšek J; Szili P; Czikkely MS; Zidar N; Janez I; Pal C; Accetto T; Pardo LA; Kikelj D; Peterlin Mašič L; Tomašič T; Bitter W; Cotman AE; Speer A; Zega A
    Eur J Med Chem; 2024 Oct; 276():116693. PubMed ID: 39053193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity.
    Govender P; Müller R; Singh K; Reddy V; Eyermann CJ; Fienberg S; Ghorpade SR; Koekemoer L; Myrick A; Schnappinger D; Engelhart C; Meshanni J; Byl JAW; Osheroff N; Singh V; Chibale K; Basarab GS
    J Med Chem; 2022 May; 65(9):6903-6925. PubMed ID: 35500229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis.
    Pandey B; Grover S; Tyagi C; Goyal S; Jamal S; Singh A; Kaur J; Grover A
    J Biomol Struct Dyn; 2018 Feb; 36(2):362-375. PubMed ID: 28071975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies.
    Saxena S; Renuka J; Jeankumar VU; Yogeeswari P; Sriram D
    Curr Top Med Chem; 2014; 14(17):1990-2005. PubMed ID: 25262795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling.
    Jeankumar VU; Reshma RS; Janupally R; Saxena S; Sridevi JP; Medapi B; Kulkarni P; Yogeeswari P; Sriram D
    Org Biomol Chem; 2015 Feb; 13(8):2423-31. PubMed ID: 25569565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
    Kale RR; Kale MG; Waterson D; Raichurkar A; Hameed SP; Manjunatha MR; Kishore Reddy BK; Malolanarasimhan K; Shinde V; Koushik K; Jena LK; Menasinakai S; Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sharma S; Nandishaiah R; Mahesh Kumar KN; Ganguly S; Ahuja V; Gaonkar S; Naveen Kumar CN; Ogg D; Boriack-Sjodin PA; Sambandamurthy VK; de Sousa SM; Ghorpade SR
    Bioorg Med Chem Lett; 2014 Feb; 24(3):870-9. PubMed ID: 24405701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update.
    Das S; Garg T; Srinivas N; Dasgupta A; Chopra S
    Curr Top Med Chem; 2019; 19(8):579-593. PubMed ID: 30834837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.